SRD5A3 is required for converting polyprenol to dolichol and is mutated in a congenital glycosylation disorder.

Neurogenetics Laboratory, Institute for Genomic Medicine, Howard Hughes Medical Institute, Department of Neurosciences and Pediatrics, University of California, San Diego, La Jolla, CA 92093, USA.
Cell (Impact Factor: 33.12). 07/2010; 142(2):203-17. DOI: 10.1016/j.cell.2010.06.001
Source: PubMed

ABSTRACT N-linked glycosylation is the most frequent modification of secreted and membrane-bound proteins in eukaryotic cells, disruption of which is the basis of the congenital disorders of glycosylation (CDGs). We describe a new type of CDG caused by mutations in the steroid 5alpha-reductase type 3 (SRD5A3) gene. Patients have mental retardation and ophthalmologic and cerebellar defects. We found that SRD5A3 is necessary for the reduction of the alpha-isoprene unit of polyprenols to form dolichols, required for synthesis of dolichol-linked monosaccharides, and the oligosaccharide precursor used for N-glycosylation. The presence of residual dolichol in cells depleted for this enzyme suggests the existence of an unexpected alternative pathway for dolichol de novo biosynthesis. Our results thus suggest that SRD5A3 is likely to be the long-sought polyprenol reductase and reveal the genetic basis of one of the earliest steps in protein N-linked glycosylation.

  • [Show abstract] [Hide abstract]
    ABSTRACT: -Compared to men, women have a better prognosis when suffering from aortic valve stenosis, hypertrophic cardiomyopathy or heart failure. Recent data suggest that androgens like testosterone or the more potent dihydrotestosterone (DHT) contribute to the development of cardiac hypertrophy and failure. Therefore, we analyzed whether anti-androgenic therapy with finasteride, which inhibits the generation of DHT by the enzyme 5-α-reductase, improves pathological ventricular remodeling and heart failure. -We found a strongly induced expression of all three isoforms of the 5-α-reductase (Srd5a1-3) in human and mouse hearts with pathological hypertrophy, which was associated with increased myocardial accumulation of DHT. Starting one week after the induction of pressure overload by transaortic constriction, mice were treated with finasteride for two weeks. Cardiac function, hypertrophy, dilation and fibrosis were markedly improved in response to finasteride treatment in male, but also in female mice. In addition, finasteride also very effectively improved cardiac function and mortality after long-term pressure overload and prevented disease progression in cardiomyopathic mice with myocardial Gαq overexpression. Mechanistically, finasteride by decreasing DHT potently inhibited hypertrophy and Akt dependent pro-hypertrophic signaling in isolated cardiac myocytes, while introduction of constitutively active Akt blunted these effects of finasteride. -Finasteride, which is currently used in patients to treat prostate disease, potently reverses pathological cardiac hypertrophy and dysfunction in mice, and might be a therapeutic option for heart failure.
    Circulation 01/2015; DOI:10.1161/CIRCULATIONAHA.114.012066 · 14.95 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: 5-Alpha reductase is an enzyme responsible for the conversion of testosterone to dihydrotestosterone. This key enzyme is responsible for triggering masculinization of the male external genitalia. Discovery of 5-alpha reductase deficiency as a syndrome of disordered male sexual development led to our molecular understanding of the role that this key enzyme plays in male sexual differentiation. This article will review the clinical and molecular history behind the discovery of 5-alpha reductase deficiency.
    Current Opinion in Endocrinology Diabetes and Obesity 10/2014; 21(6). DOI:10.1097/MED.0000000000000116 · 3.77 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Congenital disorders of glycosylation (CDG) comprise a group of inborn errors of metabolism with abnormal glycosylation of proteins and lipids. Patients with defective protein N-glycosylation are identified in routine metabolic screening via analysis of serum transferrin glycosylation. Defects in the assembly of the dolichol linked Glc3Man9GlcNAc2 glycan and its transfer to proteins lead to the (partial) absence of complete glycans on proteins. These defects are called CDG-I and are located in the endoplasmic reticulum (ER) or cytoplasm. Defects in the subsequent processing of protein bound glycans result in the presence of truncated glycans on proteins. These defects are called CDG-II and the enzymes involved are located mainly in the Golgi apparatus. In recent years, human defects have been identified in dolichol biosynthesis genes within the group of CDG-I patients. This has increased interest in dolichol metabolism, has resulted in specific recognizable clinical symptoms in CDG-I and has offered new mechanistic insights in dolichol biosynthesis. We here review its biosynthetic pathways, the clinical and biochemical phenotypes in dolichol-related CDG defects, up to the formation of dolichyl-P-mannose (Dol-P-Man), and discuss existing evidence of regulatory networks in dolichol metabolism to provide an outlook on therapeutic strategies.
    Journal of Inherited Metabolic Disease 10/2014; DOI:10.1007/s10545-014-9760-1 · 4.14 Impact Factor

Full-text (2 Sources)

Available from
Jun 1, 2014